Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCI-779 and Bevacizumab in Stage IV Renal Cell Carcinoma
NCT00112840Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2005
- Primary completion
- Aug 2010
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of temsirolimus, bevacizumab in renal cell carcinoma (RCC), sponsored by National Cancer Institute. Started May 2005; status: completed.
02
Drugs
temsirolimusbevacizumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00112840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00112840.